PT3310760T - Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1 - Google Patents

Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1

Info

Publication number: PT3310760T
Authority: PT; Portugal
Prior art keywords: tetrahydrocyclo; compound1; indol; penta; benzyloxy
Prior art date: 2015-06-22

Application number

PT167345297T

Other languages

English (en)

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-22

Filing date

2016-06-21

Publication date

2022-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56322311&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3310760(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-21 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2022-11-10 Publication of PT3310760T publication Critical patent/PT3310760T/pt

Links

MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 title 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical class OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 title 1
229940125904 compound 1 Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Enzymes And Modification Thereof (AREA)

PT167345297T 2015-06-22 2016-06-21 Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1 PT3310760T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562182841P	2015-06-22	2015-06-22
US201562207531P	2015-08-20	2015-08-20

Publications (1)

Publication Number	Publication Date
PT3310760T true PT3310760T (pt)	2022-11-10

Family

ID=56322311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT167345297T PT3310760T (pt)	2015-06-22	2016-06-21	Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1

Country Status (20)

Country	Link
US (5)	US10301262B2 (pt)
EP (2)	EP3939965A1 (pt)
JP (3)	JP6838744B2 (pt)
KR (2)	KR20230160955A (pt)
CN (1)	CN108349891B (pt)
AU (3)	AU2016284162A1 (pt)
BR (1)	BR112017027656B1 (pt)
CA (1)	CA3002551A1 (pt)
DK (1)	DK3310760T3 (pt)
EA (1)	EA201890096A1 (pt)
ES (1)	ES2929526T3 (pt)
HK (1)	HK1253714A1 (pt)
HU (1)	HUE060476T2 (pt)
IL (2)	IL285890B (pt)
MA (1)	MA42807A (pt)
MX (2)	MX2017016530A (pt)
PL (1)	PL3310760T3 (pt)
PT (1)	PT3310760T (pt)
SI (1)	SI3310760T1 (pt)
WO (1)	WO2016209809A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5856980B2 (ja)	2010-01-27	2016-02-10	アリーナファーマシューティカルズ，インコーポレイテッド	（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
UA126268C2 (uk)	2015-01-06	2022-09-14	Арена Фармасьютікалз, Інк.	СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
EA201890096A1 (ru)	2015-06-22	2018-08-31	Арена Фармасьютикалз, Инк.	КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ
KR20190113955A (ko)	2017-02-16	2019-10-08	아레나 파마슈티칼스, 인크.	장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
US11534424B2 (en)	2017-02-16	2022-12-27	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
BR112019026478A2 (pt)	2017-06-14	2020-07-14	Trevena, Inc.	compostos para modulação da atividade de s1p1 e métodos de uso dos mesmos
EP3860590B1 (en)	2018-10-03	2023-06-07	Arena Pharmaceuticals, Inc.	Etrasimod for use in methods for the treatment of scleroderma
CN109678715B (zh) *	2018-11-28	2019-11-12	中国药科大学	2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途
EP4051250A1 (en)	2019-10-31	2022-09-07	Idorsia Pharmaceuticals Ltd	Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021101854A1 (en)	2019-11-19	2021-05-27	Trevena, Inc.	Compounds and methods of preparing compounds s1p1 modulators

Family Cites Families (519)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH389134A (de)	1960-03-15	1965-03-15	Ciba Geigy	Verfahren zur Herstellung neuer Anthrachinonküpenfarbstoffe
NL293572A (pt)	1962-06-07
CH478819A (de)	1965-10-22	1969-09-30	Ciba Geigy	Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen
CH480410A (de)	1967-01-09	1969-10-31	Geigy Ag J R	Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en)	1967-01-12	1975-01-14	Max Schellenbaum	N-2-ethylhexyl-n'-aryl ureas and preparation containing them
FR1593586A (pt)	1967-10-17	1970-06-01
US3608087A (en)	1968-06-21	1971-09-21	Merck & Co Inc	Feed compositions
US3887329A (en)	1969-05-05	1975-06-03	Ciba Geigy Ag	Hexamethyl phosphotriamide-dye compositions
BE756953A (fr)	1969-10-02	1971-04-01	Merck & Co Inc	Potentialisation d'antibiotiques
US3686238A (en)	1970-01-19	1972-08-22	Syntex Corp	Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en)	1970-09-11	1974-12-03	Merck & Co Inc	Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3966744A (en)	1971-01-11	1976-06-29	Syva Company	Spin labeled compounds
US3690834A (en)	1971-01-11	1972-09-12	Syva Co	Ligand determination with spin labeled compounds by receptor displacement
DE2106585A1 (de)	1971-02-11	1972-08-24	Farbenfabriken Bayer Ag, 5090 Leverkusen	Aminothiodiazole und Thiodiazol-Azofarbstoffe
CH560197A5 (en)	1971-05-17	1975-03-27	Ciba Geigy Ag	2-alkylthio-4,6-bis (subst amino)-5-nitropyrimidines - - herbicides
CH558137A (de)	1971-05-17	1975-01-31	Ciba Geigy Ag	Mittel zur beeinflussung des pflanzenwachstums.
DE2226703A1 (de)	1972-05-25	1973-12-13	Schering Ag	Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US3966764A (en)	1972-07-10	1976-06-29	Syva Company	Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en)	1972-10-20	1974-11-19	Dow Chemical Co	Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (pt)	1972-11-16	1976-04-15	Ciba Geigy Ag
DE2340569C2 (de)	1973-08-10	1982-12-02	Bayer Ag, 5090 Leverkusen	Azofarbstoffe
AT340933B (de)	1973-08-20	1978-01-10	Thomae Gmbh Dr K	Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de)	1973-08-20	1975-03-06	Thomae Gmbh Dr K	Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4057559A (en)	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4101541A (en)	1973-12-21	1978-07-18	Ciba-Geigy Corporation	3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
CH584739A5 (pt)	1973-12-21	1977-02-15	Ciba Geigy Ag
FR2258841B1 (pt)	1974-01-29	1977-11-04	Ugine Kuhlmann
AT327605B (de)	1974-05-06	1976-02-10	Ciba Geigy Ag	Mittel zur hemmung des pflanzenwachstums
AU492126B2 (en)	1974-05-14	1975-11-20	Ciba-Geigy Ag	Nitropyrimidine derivatives
FR2306697A1 (fr)	1975-04-10	1976-11-05	Sogeras	Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
US4189579A (en)	1977-05-20	1980-02-19	The Dow Chemical Company	Aminoalkylthiopurines
US4139705A (en)	1977-05-20	1979-02-13	The Dow Chemical Company	Pyrazolopyrimidines
DE2731264A1 (de)	1977-07-11	1979-02-01	Boehringer Mannheim Gmbh	Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja)	1977-12-09	1985-09-02	コニカ株式会社	ハロゲン化銀カラ−写真感光材料
US4242507A (en)	1978-02-23	1980-12-30	Fujisawa Pharmaceutical Co., Ltd.	Sulfonic acid esters
DE2831580C2 (de)	1978-07-18	1980-09-18	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren und Reagens zur Bestimmung von Glycerin
DE2831850A1 (de)	1978-07-20	1980-02-07	Basf Ag	N-arylsulfonylpyrrole, ihre herstellung und diese enthaltende therapeutische mittel
DE2906603A1 (de)	1979-02-21	1980-09-04	Boehringer Mannheim Gmbh	N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
US4343804A (en)	1979-03-26	1982-08-10	A. H. Robins Company, Inc.	4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
DE3070304D1 (en)	1980-04-28	1985-04-25	Teijin Ltd	Thiazolo(3,2-a)pyrimidine derivatives, process for preparing same, and drug containing same
EP0053678A1 (de)	1980-12-05	1982-06-16	BASF Aktiengesellschaft	5-Amino-1-phenyl-4-cyanpyrazole, diese enthaltende herbizide Mittel, Verfahren zu ihrer Herstellung und ihre Anwendung als Herbizide
RU938559C (ru)	1980-12-12	1993-11-30	Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе	S-Производные 5-амино-6-меркаптопиримидина, обладающие противоопухолевым и цитостатическим действием
DOP1981004033A (es)	1980-12-23	1990-12-29	Ciba Geigy Ag	Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
US4476248A (en)	1983-02-28	1984-10-09	The Upjohn Company	Crystallization of ibuprofen
DE3334455A1 (de)	1983-03-04	1984-09-06	Bayer Ag, 5090 Leverkusen	Guanidin - derivate
US4612376A (en)	1983-03-25	1986-09-16	Fujisawa Pharmaceutical Co., Ltd.	Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
ZA848275B (en)	1983-12-28	1985-08-28	Degussa	New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3406329A1 (de)	1984-02-22	1985-08-22	Merck Patent Gmbh, 6100 Darmstadt	Pyridone
JPS6157587A (ja)	1984-08-29	1986-03-24	Shionogi & Co Ltd	縮合複素環誘導体および抗潰瘍剤
PH22302A (en)	1985-02-11	1988-07-22	Fujisawa Pharmaceutical Co	Piperidine compounds
DK88186A (da)	1985-03-01	1986-09-02	Duphar Int Res	Benzoylurinstofderivater med antitumoraktivitet
DE3601196A1 (de)	1986-01-17	1987-07-23	Merck Patent Gmbh	1,4-dihydropyridine
US4810699A (en)	1987-02-20	1989-03-07	American Home Products Corporation	Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
CA1340284C (en)	1987-03-19	1998-12-22	Zeneca Inc.	Herbicidal substituted cyclic diones
DE68926687T2 (de)	1988-01-11	1997-03-06	Fuji Photo Film Co Ltd	Verfahren zur Erzeugung von extrem hochkontrastreichen negativen Bildern
US4782076A (en)	1988-03-01	1988-11-01	American Home Products Corporation	Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives, composition and use
PT95692A (pt)	1989-10-27	1991-09-13	American Home Prod	Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
NZ238863A (en)	1990-07-19	1993-03-26	Janssen Pharmaceutica Nv	Substituted thiazolyl and pyridinyl derivatives
US5221678A (en)	1990-07-26	1993-06-22	Merck Frosst Canada, Inc.	(quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
WO1992012976A1 (en)	1991-01-16	1992-08-06	Yoshitomi Pharmaceutical Industries, Ltd.	Use of pyridine compound as selective drug and novel pyridine compound
CA2070978A1 (en)	1991-06-11	1992-12-12	William J. Greenlee	Cyclic renin inhibitors
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
JPH0533359A (ja)	1991-08-02	1993-02-09	Kubota Corp	全旋回型の小型バツクホウ
EP0556889A1 (en)	1992-02-18	1993-08-25	Duphar International Research B.V	Method of preparing aryl(homo)piperazines
DE4208254A1 (de)	1992-03-14	1993-09-16	Hoechst Ag	Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
TW237456B (pt)	1992-04-09	1995-01-01	Ciba Geigy
FR2692575B1 (fr)	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
NZ314207A (en)	1992-09-28	2000-12-22	Vertex Pharma	1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
DE4241632A1 (de)	1992-12-10	1994-06-16	Thomae Gmbh Dr K	Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW370529B (en)	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
US5998499A (en)	1994-03-25	1999-12-07	Dentsply G.M.B.H.	Liquid crystalline (meth)acrylate compounds, composition and method
JPH0753546A (ja)	1993-08-09	1995-02-28	Kuraray Co Ltd	ジアリール置換複素環化合物およびその医薬用途
NZ274978A (en)	1993-10-12	1998-04-27	Du Pont Merck Pharma	1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
GB9400889D0 (en)	1994-01-18	1994-03-16	Sandoz Ltd	Novel compounds
TW530047B (en)	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
HU221855B1 (hu)	1994-09-09	2003-02-28	Nippon Shinyaku Co., Ltd.	Szubsztituált piridin-, pirimidin- és triazinszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények
JP3100165B2 (ja)	1994-11-29	2000-10-16	大日本製薬株式会社	インドール誘導体
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
ATE251141T1 (de)	1995-03-10	2003-10-15	Berlex Lab	Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
IL117659A (en)	1995-04-13	2000-12-06	Dainippon Pharmaceutical Co	Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
WO1996033994A1 (fr)	1995-04-28	1996-10-31	Nippon Soda Co., Ltd.	Derives amino-substitues, leur procede de preparation et herbicide
KR100256707B1 (ko)	1995-05-12	2000-05-15	해피 페너	데아자푸린 유도체; 새로운 부류의 crf1 특이 리간드
WO1996036613A1 (fr)	1995-05-19	1996-11-21	Nippon Soda Co., Ltd.	Derives d'acides benzoiques substitues, procede de production desdits derives et herbicides
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
US6956047B1 (en)	1995-06-06	2005-10-18	Pfizer Inc.	Corticotropin releasing factor antagonists
TWI238064B (en)	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
KR0169813B1 (ko)	1995-07-12	1999-01-15	김종인	4-아미노-3-아실나프티리딘 유도체
ES2152563T3 (es)	1995-08-31	2001-02-01	Lonza Ag	Procedimiento para preparar derivados de dihidroxipirimidina.
CZ126598A3 (cs)	1995-10-26	1998-09-16	Mitsubishi-Tokyo Pharmaceuticals, Inc.	Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US5849759A (en)	1995-12-08	1998-12-15	Berlex Laboratories, Inc.	Naphthyl-substituted benzimidazole derivatives as anti-coagulants
USH2007H1 (en)	1996-01-19	2001-12-04	Fmc Corporation	Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
DE19602095A1 (de)	1996-01-22	1997-07-24	Bayer Ag	Halogenpyrimidine
ES2194179T3 (es)	1996-02-02	2003-11-16	Merck & Co Inc	Derivados heterociclicos como agentes antidiabeticos y antiobesidad.
IL123835A0 (en)	1996-02-07	1998-10-30	Janssen Pharmaceutica Nv	Pyrazolopyrimidines as CRF receptor antagonists
US5948786A (en)	1996-04-12	1999-09-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyrimidine derivatives
DE19616486C5 (de)	1996-04-25	2016-06-30	Royalty Pharma Collection Trust	Verfahren zur Senkung des Blutglukosespiegels in Säugern
DE19624659A1 (de)	1996-06-20	1998-01-08	Klinge Co Chem Pharm Fab	Neue Pyridylalken- und Pyridylalkinsäureamide
AU3176297A (en)	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
US6060478A (en)	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
US5776967A (en)	1996-07-26	1998-07-07	American Home Products Corporation	Pyranoindole inhibitors of COX--2
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
US5830911A (en)	1996-08-14	1998-11-03	American Home Products Corporation	Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
ES2273369T3 (es)	1996-08-28	2007-05-01	Pfizer Inc.	Derivados 6,5 heterobiciclicos sustituidos.
US6008234A (en)	1996-09-12	1999-12-28	Berlex Laboratories, Inc.	Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
CZ86199A3 (cs)	1996-09-12	1999-08-11	Schering Aktiengesellschaft	Benzamidinové deriváty substituované cyklickou aminokyselinou a cyklické hydrokyselinové deriváty, farmaceutický prostředek obsahující tyto látky a jejich použití jako protisrážecích činidel
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
DZ2376A1 (fr)	1996-12-19	2002-12-28	Smithkline Beecham Plc	Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
CA2229123A1 (en)	1997-02-11	1998-08-11	Mitchell Irvin Steinberg	Pharmaceutical agents
EP0970082A2 (en)	1997-02-18	2000-01-12	Neurocrine Biosciences, Inc.	Biazacyclic crf antagonists
JP2002501493A (ja)	1997-04-22	2002-01-15	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｃｒｆアンタゴニストのチオフェノピリジン類
US6482836B1 (en)	1997-04-22	2002-11-19	Charles Huang	CRF antagonistic quino- and quinazolines
JPH11193277A (ja)	1997-05-14	1999-07-21	Nippon Soda Co Ltd	ピリミジン誘導体、その製法および有害生物防除剤
DE19737723A1 (de)	1997-08-14	1999-02-18	Bayer Ag	Methoximinomethyloxadiazine
ID24435A (id)	1997-08-14	2000-07-20	Bayer Ag	Metoksiminometiloksadiazina
NL1010018C2 (nl)	1997-09-09	1999-03-10	Duphar Int Res	Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6861448B2 (en)	1998-01-14	2005-03-01	Virtual Drug Development, Inc.	NAD synthetase inhibitors and uses thereof
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
EP1068206A1 (en)	1998-04-02	2001-01-17	Neurogen Corporation	Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
AU5777299A (en)	1998-08-21	2000-03-14	Du Pont Pharmaceuticals Company	Isoxazolo(4,5-d)pyrimidines as CRF antagonists
OA11674A (en)	1998-11-10	2005-01-12	Janssen Pharmaceutica Nv	HIV Replication inhibiting pyrimidines.
US6262088B1 (en)	1998-11-19	2001-07-17	Berlex Laboratories, Inc.	Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
JP2003534767A (ja)	1998-11-20	2003-11-25	アリーナ・フアーマシユーチカルズ・インコーポレーテツド	ヒトオーファンｇタンパク質共役型受容体
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6239126B1 (en)	1998-12-17	2001-05-29	American Home Products Corporation	Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
BR9916220A (pt)	1998-12-17	2001-09-11	American Home Prod	Derivados de arilpiperidina e aril-1,2,5,6-tetraidropiridina uréia tendo atividade de receptor 5ht1a
US6867200B1 (en)	1998-12-18	2005-03-15	Axys Pharmaceuticals, Inc.	(Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6267985B1 (en)	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
ES2219319T3 (es)	1999-03-17	2004-12-01	Astrazeneca Ab	Derivados de amida.
EP1040831A3 (en)	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
ES2287016T3 (es)	1999-04-28	2007-12-16	Sanofi-Aventis Deutschland Gmbh	Derivados de diaril-acido como ligandos del receptor ppar.
KR20020027463A (ko)	1999-07-12	2002-04-13	우에노 도시오	스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
EP1074549B1 (en)	1999-08-06	2003-11-19	F. Hoffmann-La Roche Ag	Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
EP1212327B8 (en)	1999-09-17	2004-02-25	Abbott GmbH & Co. KG	Pyrazolopyrimidines as therapeutic agents
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP2001089452A (ja)	1999-09-22	2001-04-03	Sankyo Co Ltd	ピリミジン誘導体
ATE316781T1 (de)	1999-09-24	2006-02-15	Janssen Pharmaceutica Nv	Antivirale feste dispersionen
KR20020047198A (ko)	1999-09-30	2002-06-21	해피 페너 ; 해리 에이치. 페너 2세	특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
CA2379633C (en)	1999-09-30	2006-06-20	Neurogen Corporation	Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
CA2379640C (en)	1999-09-30	2006-11-28	Neurogen Corporation	Certain alkylene diamine-substituted heterocycles
DE19947154A1 (de)	1999-10-01	2001-10-04	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US6887870B1 (en)	1999-10-12	2005-05-03	Bristol-Myers Squibb Company	Heterocyclic sodium/proton exchange inhibitors and method
CO5271670A1 (es)	1999-10-29	2003-04-30	Pfizer Prod Inc	Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
GR990100388A (el)	1999-11-09	2001-07-31		Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....
US6448429B1 (en)	1999-12-22	2002-09-10	Merck Frosst Canada & Co.	Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
DE19962936A1 (de)	1999-12-24	2001-06-28	Bayer Ag	Neue beta-Aminosäureverbindungen als Integrinantagonisten
SK11062002A3 (sk)	1999-12-30	2002-12-03	H. Lundbeck A/S	Fenylpiperazínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
CA2397633A1 (en)	2000-01-18	2001-07-26	Pfizer Products Inc.	Corticotropin releasing factor antagonists
SK11202002A3 (sk)	2000-02-09	2003-03-04	Hokuriku Seiyaku Co., Ltd.	Deriváty 1H-imidazopyridínu
JP2003523418A (ja)	2000-02-15	2003-08-05	フオスター・ミラー・インコーポレイテツド	揮発性有機成分を含まない放射硬化性樹脂組成物
US6569879B2 (en)	2000-02-18	2003-05-27	Merck & Co., Inc.	Aryloxyacetic acids for diabetes and lipid disorders
AU784722B2 (en)	2000-02-18	2006-06-01	Merck & Co., Inc.	Aryloxyacetic acids for diabetes and lipid disorders
ATE293962T1 (de)	2000-02-25	2005-05-15	Hoffmann La Roche	Adenosin-rezeptor modulatoren
CN1651087A (zh)	2000-04-12	2005-08-10	诺瓦提斯公司	有机化合物的联合形式
US7034019B2 (en)	2000-05-08	2006-04-25	Janssen Pharmaceutica N.V.	Prodrugs of HIV replication inhibiting pyrimidines
DE10024319A1 (de)	2000-05-17	2001-11-22	Merck Patent Gmbh	Bisacylguanidine
DK1287133T3 (da)	2000-05-18	2007-03-26	Bayer Healthcare Ag	Regulering af human dopamin-lignende G-protein-koblet receptor
JP2003533530A (ja)	2000-05-18	2003-11-11	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆレセプターアンタゴニスト
CZ20024199A3 (cs)	2000-05-25	2004-01-14	F. Hoffmann-La Roche Ag	Substituované 1-aminoalkyllaktamy a jejich použití jako antagonisty muskarinového receptoru
US6620821B2 (en)	2000-06-15	2003-09-16	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
MXPA02012795A (es)	2000-06-28	2004-07-30	Teva Pharma	Carvedilol.
NZ523445A (en)	2000-06-29	2004-10-29	Abbott Lab	Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
AR028782A1 (es)	2000-07-05	2003-05-21	Taisho Pharmaceutical Co Ltd	Derivados heterociclicos tetrahidropiridino o piperidino
US6444685B1 (en)	2000-07-17	2002-09-03	Wyeth	N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
AU2001269529A1 (en)	2000-07-18	2002-01-30	Yamanouchi Pharmaceutical Co., Ltd.	Medicine comprising dicyanopyridine derivative
CA2415742A1 (en)	2000-07-25	2002-01-31	Merck & Co., Inc.	N-substituted indoles useful in the treatment of diabetes
US6410583B1 (en)	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2002019975A1 (fr)	2000-09-05	2002-03-14	Taisho Pharmaceutical Co., Ltd.	Stimulants de la croissance des cheveux
AU2001262945B2 (en)	2000-09-20	2006-02-02	Skyepharma Canada Inc.	Spray drying process and compositions of fenofibrate
US20030224058A1 (en)	2002-05-24	2003-12-04	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US7276249B2 (en)	2002-05-24	2007-10-02	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
PE20020507A1 (es)	2000-10-17	2002-06-25	Schering Corp	Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2002032408A2 (en)	2000-10-20	2002-04-25	Novartis Ag	Combinations of a thyromimetic compound and a statin
EP2404603A1 (en)	2000-10-23	2012-01-11	Glaxosmithkline LLC	Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
WO2002060434A2 (en)	2000-10-31	2002-08-08	Merck & Co., Inc.	Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
AU3958902A (en)	2000-11-03	2002-05-27	Neurocrine Biosciences Inc	Crf receptor antagonists and methods relating thereto
US20020058026A1 (en)	2000-11-13	2002-05-16	Milton Hammerly	HMG CoA reductase inhibitor medications combined wih CoEnzyme Q-10
WO2002039987A2 (en)	2000-11-14	2002-05-23	Neurosearch A/S	Use of malaria parasite anion channel blockers for treating malaria
US7022725B2 (en)	2000-11-17	2006-04-04	Takeda Pharmaceutical Company Limited	Isoxazole derivatives
UA77165C2 (en)	2000-11-17	2006-11-15	Lilly Co Eli	(n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
AU2426602A (en)	2000-11-20	2002-05-27	Biovitrum Ab	Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
US20030180813A1 (en)	2000-12-01	2003-09-25	Takahide Ohishi	Method of screening remedy for diabetes
US20020137755A1 (en)	2000-12-04	2002-09-26	Bilodeau Mark T.	Tyrosine kinase inhibitors
US6545016B1 (en)	2000-12-08	2003-04-08	3M Innovative Properties Company	Amide substituted imidazopyridines
US6525064B1 (en)	2000-12-08	2003-02-25	3M Innovative Properties Company	Sulfonamido substituted imidazopyridines
US6545017B1 (en)	2000-12-08	2003-04-08	3M Innovative Properties Company	Urea substituted imidazopyridines
US20020107262A1 (en)	2000-12-08	2002-08-08	3M Innovative Properties Company	Substituted imidazopyridines
JP4405726B2 (ja)	2000-12-21	2010-01-27	ブリストル−マイヤーズスクイブカンパニー	Ｔｅｃファミリーチロシンキナーゼのチアゾリルインヒビター
CZ305202B6 (cs)	2001-01-26	2015-06-10	Merck Sharp & Dohme Corp.	Farmaceutický prostředek
CA2434491A1 (en)	2001-01-30	2002-08-08	Merck & Co., Inc.	Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
WO2002064616A2 (en)	2001-01-30	2002-08-22	University Of Virgina Patent Foundation	Agonists and antagonists of sphingosine-1-phosphate receptors
BR0207302A (pt)	2001-02-08	2004-02-10	Memory Pharm Corp	Trifluorometilpurinas como inibidores da fosfodiesterase 4
CA2437118A1 (en)	2001-02-09	2002-08-22	Merck & Co., Inc.	2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
DE10110754A1 (de)	2001-03-07	2002-09-19	Bayer Ag	Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
WO2002072101A1 (en)	2001-03-13	2002-09-19	Bristol-Myers Squibb Pharma Company	A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
WO2002079131A1 (fr)	2001-03-29	2002-10-10	Kansai Research Institute, Inc.	Compose optiquement actif et composition de resine photosensible
WO2002081454A1 (en)	2001-04-09	2002-10-17	Dr. Reddy's Laboratories Ltd.	Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
HUP0303958A2 (hu)	2001-04-20	2004-04-28	Wyeth	Heterociklusos oxi-, tioxi- és amino-benzazol-származékok, mint 5-hidroxitriptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE416762T1 (de)	2001-05-10	2008-12-15	Ono Pharmaceutical Co	Carbonsäurederivate und diese als wirkstoff enthaltende arzneimittel
KR100602927B1 (ko)	2001-06-01	2006-07-20	에프. 호프만-라 로슈 아게	글루타메이트 수용체로서의 피리미딘, 트리아진 및 피라진유도체
JP2005500294A (ja)	2001-06-19	2005-01-06	ブリストル−マイヤーズ　スクイブ　カンパニー	ホスホジエステラーゼ７に対するピリミジン阻害剤
US6825198B2 (en)	2001-06-21	2004-11-30	Pfizer Inc	5-HT receptor ligands and uses thereof
EP1406875B1 (en)	2001-06-26	2013-07-31	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of tnf-alpha expression
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0117899D0 (en)	2001-07-23	2001-09-12	Astrazeneca Ab	Chemical compounds
WO2003026661A1 (fr)	2001-09-14	2003-04-03	Yamanouchi Pharmaceutical Co., Ltd.	Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
CN1329372C (zh)	2001-09-27	2007-08-01	杏林制药株式会社	二芳基硫醚衍生物及其加成盐和免疫抑制剂
JP2005506350A (ja)	2001-10-18	2005-03-03	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物
SE0104334D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
GB0229931D0 (en)	2002-12-21	2003-01-29	Astrazeneca Ab	Therapeutic agents
WO2003059378A2 (en)	2001-12-29	2003-07-24	Novo Nordisk A/S	Combined use of a glp-1 compound and another drug for treating dyslipidemia
US20050043315A1 (en)	2002-01-02	2005-02-24	Hideo Tsutsumi	Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
US20070225351A1 (en)	2002-01-11	2007-09-27	Lippa Arnold S	Methods and compositions for controlling body weight and appetite
AU2003205630A1 (en)	2002-01-18	2003-07-30	The Genetics Company Inc.	Beta-secretase inhibitors
AU2003216054B2 (en)	2002-01-18	2007-01-04	Merck & Co., Inc.	Selective S1P1/Edg1 receptor agonists
US7479504B2 (en)	2002-01-18	2009-01-20	Merck & Co., Inc.	Edg receptor agonists
GB0201850D0 (en)	2002-01-26	2002-03-13	Astrazeneca Ab	Therapeutic treatment
AU2003217764A1 (en)	2002-03-01	2003-09-16	Merck & Co., Inc.	Aminoalkylphosphonates and related compounds as edg receptor agonists
AU2003218056A1 (en)	2002-03-01	2003-09-16	Merck & Co., Inc.	Aminoalkylphosphonates and related compounds as edg receptor agonists
DE60336901D1 (de)	2002-03-07	2011-06-09	X Ceptor Therapeutics Inc	Chinazolinon modulatoren von nukleinrezeptoren
CN1642422A (zh)	2002-03-15	2005-07-20	西巴特殊化学品控股有限公司	4－氨基嘧啶及其在表面抗菌处理中的应用
PE20040291A1 (es)	2002-03-22	2004-07-02	Novartis Ag	COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
WO2003088962A1 (en)	2002-04-16	2003-10-30	Merck & Co., Inc.	Combination therapy using a ppar alpha/gamma agonist
AU2003222786A1 (en)	2002-04-18	2003-10-27	Ucb, S.A.	Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
DE10219435A1 (de)	2002-05-02	2003-11-13	Bayer Cropscience Ag	Substituierte Pyrazolo-pyrimidin-4-one
AU2003225305A1 (en)	2002-05-08	2003-11-11	Bristol-Myers Squibb Company	Pyridine-based thyroid receptor ligands
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
JP2005531606A (ja)	2002-06-10	2005-10-20	エランファーマインターナショナル，リミティド	ナノ粒子ステロール製剤およびステロールの組合せ
WO2003103632A1 (en)	2002-06-10	2003-12-18	Elan Pharma International, Ltd.	Nanoparticulate polycosanol formulations and novel polycosanol combinations
AR040241A1 (es)	2002-06-10	2005-03-23	Merck & Co Inc	Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
AU2003245313A1 (en)	2002-06-10	2003-12-22	Elan Pharma International, Ltd	Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
WO2003105763A2 (en)	2002-06-14	2003-12-24	Amylin Pharmaceuticals, Inc.	Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
AU2003276043A1 (en)	2002-06-17	2003-12-31	Merck & Co., Inc.	1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
DE10226943A1 (de)	2002-06-17	2004-01-08	Bayer Ag	Phenylaminopyrimidine und ihre Verwendung
GB0214254D0 (en)	2002-06-20	2002-07-31	Glaxo Group Ltd	Chemical compounds
SE0201976D0 (sv)	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
SE0201980D0 (sv)	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
US20060014717A1 (en)	2002-06-28	2006-01-19	Glykos Finland Oy	Therapeutic compositions for use in prophylaxis or treatment of diarrheas
US7071210B2 (en)	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en)	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
EP1541563A4 (en)	2002-07-10	2007-11-07	Ono Pharmaceutical Co	ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
US20050267133A1 (en)	2002-07-23	2005-12-01	Brown Matthew L	Pyrazolopyrimidines as kinase inhibitors
WO2004009602A1 (en)	2002-07-23	2004-01-29	Smithkline Beecham Corporation	Pyrazolopyrimidines as kinase inhibitors
WO2004009597A2 (en)	2002-07-23	2004-01-29	Smithkline Beecham Corporation	Pyrazolopyrimidines as protein kinase inhibitors
AU2003258542A1 (en)	2002-07-29	2004-02-23	Axxima Pharmaceuticals Ag	Method for isolating atp binding proteins by means of immobolized protein inhibitors
CA2533587A1 (en)	2002-07-30	2004-02-05	University Of Virginia Patent Foundation	Compounds active in sphingosine 1-phosphate signaling
DE60322075D1 (de)	2002-07-30	2008-08-21	Merck & Co Inc	Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
US7297715B2 (en)	2002-07-30	2007-11-20	Merck & Co., Inc.	PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
JP2004067575A (ja)	2002-08-06	2004-03-04	Yaizu Suisankagaku Industry Co Ltd	糖尿病治療薬効果促進剤
MXPA05001456A (es)	2002-08-08	2005-06-06	Amgen Inc	Ligandos del receptor vanilloide y su uso en tratamientos.
DE10237722A1 (de)	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2006500378A (ja)	2002-08-21	2006-01-05	メルク　エンド　カムパニー　インコーポレーテッド	二元ＰＰＡＲα／γアゴニストとアンギオテンシンＩＩのＩ型受容体アンタゴニストを使用する併用療法
ES2342596T3 (es)	2002-08-29	2010-07-09	MERCK SHARP & DOHME CORP.	Indoles con actividad anti-diabetica.
AU2003260085B2 (en)	2002-08-29	2008-09-11	Merck & Co., Inc.	Indoles having anti-diabetic activity
JPWO2004024943A1 (ja)	2002-09-11	2006-01-12	アステラス製薬株式会社	インスリン含量増加剤スクリーニング方法
JP2006510597A (ja)	2002-09-27	2006-03-30	メルク　エンド　カムパニー　インコーポレーテッド	置換ピリミジン類
US7067658B2 (en)	2002-09-30	2006-06-27	Bristol-Myers Squibb Company	Pyridino and pyrimidino pyrazinones
AU2003282679A1 (en)	2002-10-04	2004-05-04	Arena Pharmaceuticals, Inc.	Hydroxypyrazoles for use against metabolic-related disorders
AU2003284111A1 (en)	2002-10-09	2004-05-04	Genaissance Pharmaceuticals, Inc.	Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
AU2003301302A1 (en)	2002-10-15	2004-05-04	Smithkline Beecham Corporation	Pyradazine compounds as gsk-3 inhibitors
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
WO2004041164A2 (en)	2002-10-30	2004-05-21	Merck & Co., Inc.	Kinase inhibitors
EP1559422B1 (en)	2002-11-08	2014-04-30	Takeda Pharmaceutical Company Limited	Receptor function controlling agent
US7098235B2 (en)	2002-11-14	2006-08-29	Bristol-Myers Squibb Co.	Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20040110241A1 (en)	2002-12-06	2004-06-10	Segal Mark S.	Materials and methods for monitoring vascular endothelial function
JO2397B1 (en)	2002-12-20	2007-06-17	ميرك شارب اند دوم كوربوريشن	Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
AU2003299791A1 (en)	2002-12-20	2004-07-22	Bayer Pharmaceuticals Corporation	Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2004058174A2 (en)	2002-12-20	2004-07-15	Bayer Pharmaceuticals Corporation	Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
JP4516430B2 (ja)	2002-12-20	2010-08-04	メルク・シャープ・エンド・ドーム・コーポレイション	１−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール
GB0230021D0 (en)	2002-12-23	2003-01-29	Syngenta Ltd	Fungicides
GB0230020D0 (en)	2002-12-23	2003-01-29	Syngenta Ltd	Fungicides
US8293751B2 (en)	2003-01-14	2012-10-23	Arena Pharmaceuticals, Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
ES2285409T3 (es)	2003-01-16	2007-11-16	Sb Pharmco Puerto Rico Inc	Derivados pirrol(2,3-b)piridina sustituidos con heteroarilo como antagonistas del receptor de crf.
WO2004066963A2 (en)	2003-01-17	2004-08-12	Merck & Co., Inc.	N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
GB0301259D0 (en)	2003-01-20	2003-02-19	Novartis Ag	Organic compounds
WO2004071442A2 (en)	2003-02-11	2004-08-26	Irm Llc	Novel bicyclic compounds and compositions
TW200418829A (en)	2003-02-14	2004-10-01	Avanir Pharmaceutics	Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
EP2172472B1 (en)	2003-02-18	2012-12-26	Kyorin Pharmaceutical Co., Ltd.	Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor
EP1606282B1 (en)	2003-02-24	2008-11-12	Arena Pharmaceuticals, Inc.	Phenyl- and pyridylpipereidinye-derivatives as modulators of glucose metabolism
JP2004269468A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
JP2004269469A (ja)	2003-03-12	2004-09-30	Yamanouchi Pharmaceut Co Ltd	ピリミジン誘導体又はその塩
JP2006521344A (ja)	2003-03-28	2006-09-21	ファイザー・プロダクツ・インク	アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
WO2004096752A1 (en)	2003-04-30	2004-11-11	Novartis Ag	Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
MXPA05011597A (es)	2003-04-30	2005-12-15	Novartis Ag	Derivados de aminopropanol como moduladores del receptor 1-fosfato de esfingosina.
JP2006525366A (ja)	2003-04-30	2006-11-09	ジインスチチュートフォーファーマシューティカルディスカバリー、エルエルシー	複素環式カルボン酸置換基
TWI494102B (zh)	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
ATE475421T1 (de)	2003-05-06	2010-08-15	Ustav Ex Botan Akademie Ved Ce	Pyrazoloä4,3-düpyrimidines, verfahren zur ihre herstellung und deren verwendung
US7083933B1 (en)	2003-05-09	2006-08-01	Prosidion Limited	Methods for identification of modulators of OSGPR116 activity
SE0301368D0 (sv)	2003-05-09	2003-05-09	Astrazeneca Ab	Chemical compounds
AU2004240586A1 (en)	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2004104205A2 (en)	2003-05-16	2004-12-02	Merck & Co., Inc.	Enzymatic preparation of chiral indole esters
MY150088A (en)	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
CN1791592B (zh)	2003-05-19	2012-07-04	Irm责任有限公司	免疫抑制剂化合物和组合物
US7417065B2 (en)	2003-05-19	2008-08-26	Irm Llc	Immunosuppressant compounds and compositions
CA2524027C (en)	2003-05-19	2013-03-19	Irm Llc	Immunosuppressant compounds and compositions
US6987118B2 (en)	2003-05-21	2006-01-17	Pfizer Inc.	Tetrahydroisoquinoline derivatives as PPAR-alpha activators
US20060160834A1 (en)	2003-06-06	2006-07-20	Fong Tung M	Combination therapy for the treatment of hypertension
AU2003902882A0 (en)	2003-06-10	2003-06-26	Fujisawa Pharmaceutical Co., Ltd.	Piperidyl derivatives
GB0313612D0 (en)	2003-06-12	2003-07-16	Novartis Ag	Organic compounds
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en)	2003-07-14	2009-12-03	Arena Pharmaceuticals,Inc	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP1661879A4 (en)	2003-08-04	2006-11-29	Ono Pharmaceutical Co	A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2005016894A1 (en)	2003-08-15	2005-02-24	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
ATE449069T1 (de)	2003-08-28	2009-12-15	Novartis Pharma Gmbh	Aminopropanolderivate
AU2004268455B2 (en)	2003-08-29	2009-12-17	Ono Pharmaceutical Co., Ltd.	Compound capable of binding S1P receptor and pharmaceutical use thereof
CN1874991A (zh)	2003-08-29	2006-12-06	小野药品工业株式会社	能够结合s1p受体的化合物及其药物用途
JP2007504230A (ja)	2003-09-02	2007-03-01	メルク　エンド　カムパニー　インコーポレーテッド	ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
WO2005023762A1 (en)	2003-09-04	2005-03-17	Abbott Laboratories	Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
WO2005023771A1 (ja)	2003-09-05	2005-03-17	Ono Pharmaceutical Co., Ltd.	ケモカインレセプターアンタゴニストおよびその医薬用途
MY148123A (en)	2003-09-05	2013-02-28	Vertex Pharma	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP2007505121A (ja)	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
WO2005030751A2 (en)	2003-09-08	2005-04-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
PE20050948A1 (es)	2003-09-09	2005-12-16	Japan Tobacco Inc	Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
WO2005030127A2 (en)	2003-09-23	2005-04-07	Merck & Co., Inc.	Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
JP4722851B2 (ja)	2003-09-23	2011-07-13	メルク・シャープ・エンド・ドーム・コーポレイション	キノリンカリウムチャネル阻害剤
AU2004277947A1 (en)	2003-10-01	2005-04-14	Merck & Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
WO2005033099A2 (en)	2003-10-03	2005-04-14	Glenmark Pharmaceuticals Ltd.	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2005037215A2 (en)	2003-10-14	2005-04-28	Massachusetts Institute Of Technology	Compositions and methods for enhancing cognitive function and synaptic plasticity
GB0324236D0 (en)	2003-10-16	2003-11-19	Astrazeneca Ab	Chemical compounds
PE20050444A1 (es)	2003-10-31	2005-08-09	Takeda Pharmaceutical	Compuestos de piridina como inhibidores de la peptidasa
WO2005041899A2 (en)	2003-11-03	2005-05-12	University Of Virginia Patent Foundation	Orally available sphingosine 1-phosphate receptor agonists and antagonists
US7338951B2 (en)	2003-11-10	2008-03-04	Synta Pharmaceuticals Corp.	Pyridine compounds
WO2005044780A1 (ja)	2003-11-10	2005-05-19	Kyorin Pharmaceutical Co., Ltd.	アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
ES2524916T3 (es)	2003-11-12	2014-12-15	Sino-Med International Alliance, Inc.	Compuestos heterocíclicos de ácido borónico
MY141220A (en)	2003-11-17	2010-03-31	Astrazeneca Ab	Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005058315A1 (en)	2003-12-12	2005-06-30	Ribapharm, Inc.	Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
WO2005058849A1 (en)	2003-12-15	2005-06-30	Glenmark Pharmaceuticals Ltd.	New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them
US7605171B2 (en)	2003-12-17	2009-10-20	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
GB0329498D0 (en)	2003-12-19	2004-01-28	Novartis Ag	Organic compounds
ATE528276T1 (de)	2003-12-19	2011-10-15	Ono Pharmaceutical Co	Lysophosphatidylsäurerezeptor-antagonistische verbindungen und ihre anwendungen
DE10360835A1 (de)	2003-12-23	2005-07-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
JP4958560B2 (ja)	2003-12-24	2012-06-20	プロシディオン・リミテッド	Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
WO2005072530A1 (en)	2004-01-16	2005-08-11	Merck & Co., Inc.	Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
GB0401332D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
WO2005075426A1 (en)	2004-02-03	2005-08-18	Glenmark Pharmaceuticals Ltd.	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
JP2007522233A (ja)	2004-02-11	2007-08-09	アムジエン・インコーポレーテツド	バニロイド受容体リガンド及び治療におけるそれらの使用
TW200530236A (en)	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
NZ549162A (en)	2004-02-24	2009-12-24	Sankyo Co	Amino-pyrrol alcohol compounds
EP1718604A4 (en)	2004-02-24	2008-02-13	Irm Llc	COMPOUNDS AND COMPOSITIONS OF IMMUNOSUPPRESSANTS
TW200538433A (en)	2004-02-24	2005-12-01	Irm Llc	Immunosuppressant compounds and compositiions
AU2005219791B2 (en)	2004-03-05	2011-06-09	Msd K.K.	Diaryl-substituted five-membered heterocycle derivative
GB0405289D0 (en)	2004-03-09	2004-04-21	Novartis Ag	Organic compounds
GB0405933D0 (en)	2004-03-16	2004-04-21	Glaxo Group Ltd	Compounds
AU2005230897B2 (en)	2004-04-02	2011-03-03	Merck Sharp & Dohme Corp.	Asymmetric hydrogenation process useful for the preparation of cycloalkanoindole derivatives
CA2562827A1 (en)	2004-04-12	2005-10-27	Sankyo Company Limited	Thienopyridine derivatives
AU2005249380C1 (en)	2004-04-23	2012-09-20	Exelixis, Inc.	Kinase modulators and methods of use
DK1756084T3 (da)	2004-06-04	2009-03-23	Arena Pharm Inc	Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
WO2005123677A1 (en)	2004-06-16	2005-12-29	Actelion Pharmaceuticals Ltd	4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
JP5315611B2 (ja)	2004-06-23	2013-10-16	小野薬品工業株式会社	Ｓ１ｐ受容体結合能を有する化合物およびその用途
EP1772145B1 (en)	2004-07-16	2011-03-23	Kyorin Pharmaceutical Co., Ltd.	Method of effectively using medicine and method concerning prevention of side effect
JP2007284350A (ja)	2004-07-27	2007-11-01	Takeda Chem Ind Ltd	糖尿病治療剤
WO2006010379A1 (en)	2004-07-29	2006-02-02	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as immunosuppressive agents
TW200611687A (en)	2004-07-29	2006-04-16	Sankyo Co	Pharmaceutical compositions used for immunosuppressant
US8022225B2 (en)	2004-08-04	2011-09-20	Taisho Pharmaceutical Co., Ltd	Triazole derivative
AU2005272619A1 (en)	2004-08-13	2006-02-23	Praecis Pharmaceuticals, Inc.	Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity
US20060223866A1 (en)	2004-08-13	2006-10-05	Praecis Pharmaceuticals, Inc.	Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
BRPI0515499A (pt)	2004-09-20	2008-07-29	Xenon Pharmaceuticals Inc	derivados de piridina para a inibição de estearoil-coa-desaturase humana
MX2007003371A (es)	2004-09-23	2007-05-07	Wyeth Corp	Derivados de carbazol y ciclopentaindol para tratar infeccion con virus de hepatitis c.
EP1796669B1 (en)	2004-10-01	2010-09-22	Merck Sharp & Dohme Corp.	Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7557112B2 (en)	2004-10-08	2009-07-07	Astellas Pharma Inc.	Aromatic-ring-fused pyrimidine derivative
BRPI0515992A (pt)	2004-10-12	2008-08-19	Forbes Medi Tech Res Inc	compostos e métodos para o tratamento de resistência à insulina e cardiomiopatia
TW200621257A (en)	2004-10-20	2006-07-01	Astellas Pharma Inc	Pyrimidine derivative fused with nonaromatic ring
PL1650186T3 (pl)	2004-10-22	2008-11-28	Bioprojet Soc Civ	Nowe pochodne kwasów dikarboksylowych
CA2583681A1 (en)	2004-10-22	2006-05-04	Merck & Co., Inc.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
AR051596A1 (es)	2004-10-26	2007-01-24	Irm Llc	Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
EP1812080B1 (en)	2004-11-03	2014-07-09	Arena Pharmaceuticals, Inc.	Gpr41 and modulators thereof for the treatment of insulin-related disorders
GB0425035D0 (en)	2004-11-12	2004-12-15	Novartis Ag	Organic compounds
EP1844043A2 (en)	2004-11-18	2007-10-17	The Institutes for Pharmaceutical Discovery, LLC	Heterocycle substituted carboxylic acids for the treatment of diabetes
JPWO2006057448A1 (ja)	2004-11-26	2008-06-05	武田薬品工業株式会社	アリールアルカン酸誘導体
WO2006060808A1 (en)	2004-12-03	2006-06-08	Teva Pharmaceutical Industries Ltd.	Ezetimibe polymorphs
WO2006063033A2 (en)	2004-12-06	2006-06-15	University Of Virginia Patent Foundation	Aryl amide sphingosine 1-phosphate analogs
KR101262400B1 (ko)	2004-12-13	2013-05-08	오노 야꾸힝 고교 가부시키가이샤	아미노카르복실산 유도체 및 그 의약 용도
CN101119748A (zh)	2004-12-13	2008-02-06	第一三共株式会社	用于治疗糖尿病的药物组合物
JP5065908B2 (ja)	2004-12-24	2012-11-07	プロシディオン・リミテッド	Ｇタンパク質結合受容体作動薬
NZ556017A (en)	2004-12-24	2009-10-30	Prosidion Ltd	G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
GB0428514D0 (en)	2004-12-31	2005-02-09	Prosidion Ltd	Compounds
DOP2006000008A (es)	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en)	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es)	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
DOP2006000009A (es)	2005-01-13	2006-08-15	Arena Pharm Inc	Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
US20080124384A1 (en)	2005-01-19	2008-05-29	Blum Charles A	Heteroaryl Substituted Piperazinyl-Pyridine Analogues
JP5798282B2 (ja)	2005-01-25	2015-10-21	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	メソゲン性化合物、液晶媒体および液晶ディスプレイ
EP1685841A1 (en)	2005-01-31	2006-08-02	Bayer Health Care Aktiengesellschaft	Prevention and treatment of thromboembolic disorders
US7754703B2 (en)	2005-02-14	2010-07-13	University Of Virginia Patent Foundation	Cycloalkane-containing sphingosine 1-phosphate agonists
EP1863475B1 (en)	2005-03-23	2011-09-07	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
AU2006226020A1 (en)	2005-03-23	2006-09-28	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as sphingosine-l-phosphate-1 receptor agonists
CN101180290B (zh)	2005-03-23	2012-12-12	埃科特莱茵药品有限公司	氢化苯并〔c〕噻吩衍生物作为免疫调节剂
BRPI0612028A2 (pt)	2005-06-08	2010-10-13	Novartis Ag	oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2006132406A1 (ja)	2005-06-09	2006-12-14	Banyu Pharmaceutical Co., Ltd.	下痢を伴う疾患の治療剤としてのnpy y2アゴニスト
TWI418350B (zh)	2005-06-24	2013-12-11	Sankyo Co	含有ｐｐａｒ調節劑之醫藥組成物的用途
CN101203503B (zh)	2005-06-24	2011-12-28	埃科特莱茵药品有限公司	新颖噻吩衍生物
KR20080025190A (ko)	2005-06-30	2008-03-19	프로시디온 리미티드	Ｇ-단백질 결합된 수용체 효능제
ATE527253T1 (de)	2005-07-01	2011-10-15	Irm Llc	Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer
US20070060573A1 (en)	2005-08-10	2007-03-15	Lars Wortmann	Acyltryptophanols
CA2619101A1 (en)	2005-08-23	2007-03-01	Irm Llc	Immunosuppressant compounds and compositions
NZ565898A (en)	2005-09-16	2010-07-30	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
TW200745055A (en)	2005-09-23	2007-12-16	Organon Nv	4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
WO2007037196A1 (ja)	2005-09-29	2007-04-05	Yamamoto Chemicals, Inc.	インドリン系化合物及びその製造方法
ES2385580T3 (es)	2005-10-07	2012-07-26	Kyorin Pharmaceutical Co., Ltd.	Agente terapéutico para enfermedades hepáticas que contiene un derivado de 2-amino-1,3-propanodiol como ingrediente activo
AR057894A1 (es)	2005-11-23	2007-12-26	Actelion Pharmaceuticals Ltd	Derivados de tiofeno
CA2630714C (en)	2005-11-23	2014-01-14	Epix Delaware, Inc.	S1p receptor modulating compounds and use thereof
CN103265495B (zh)	2005-12-29	2016-11-16	莱西肯医药有限公司	多环氨基酸衍生物及其使用方法
TWI404706B (zh)	2006-01-11	2013-08-11	Actelion Pharmaceuticals Ltd	新穎噻吩衍生物
TW200736234A (en)	2006-01-17	2007-10-01	Astrazeneca Ab	Chemical compounds
AU2006335967B2 (en)	2006-01-19	2012-01-19	Orchid Chemicals & Pharmaceuticals Limited	Novel heterocycles
CN101370805B (zh)	2006-01-24	2011-04-27	埃科特莱茵药品有限公司	吡啶衍生物
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
TWI389683B (zh)	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2007212193A1 (en)	2006-02-09	2007-08-16	University Of Virginia Patent Foundation	Bicyclic sphingosine 1-phosphate analogs
TW200806611A (en)	2006-02-09	2008-02-01	Daiichi Seiyaku Co	Novel amidopropionic acid derivatives and medicine containing the same
US20070191371A1 (en)	2006-02-14	2007-08-16	Kalypsys, Inc.	Heterocyclic modulators of ppar
EP1984334B1 (en)	2006-02-15	2014-04-09	Allergan, Inc.	Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
CN101460458A (zh)	2006-02-15	2009-06-17	阿勒根公司	具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
KR20080096780A (ko)	2006-02-21	2008-11-03	유니버시티 오브 버지니아 페이턴트 파운데이션	Ｓ１ｐ 수용체 효능제로서의 페닐-시클로알킬 및 페닐-헤테로시클릭 유도체
US7649098B2 (en)	2006-02-24	2010-01-19	Lexicon Pharmaceuticals, Inc.	Imidazole-based compounds, compositions comprising them and methods of their use
MX2008011615A (es)	2006-03-14	2008-09-22	Amgen Inc	Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos.
TW200806633A (en)	2006-03-21	2008-02-01	Epix Pharm Inc	S1P receptor modulating compounds and use thereof
JP2007262009A (ja)	2006-03-29	2007-10-11	Dai Ichi Seiyaku Co Ltd	ヘテロアリール低級カルボン酸誘導体
MX2008012738A (es)	2006-04-03	2009-02-06	Astellas Pharma Inc	Heterocompuesto.
DK1971862T3 (da)	2006-04-11	2011-02-14	Arena Pharm Inc	Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
GB0607389D0 (en)	2006-04-12	2006-05-24	Novartis Ag	Organic compounds
JPWO2007129745A1 (ja)	2006-05-09	2009-09-17	第一三共株式会社	ヘテロアリールアミド低級カルボン酸誘導体
AU2007251282A1 (en)	2006-05-09	2007-11-22	Pfizer Products Inc.	Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2007129473A1 (ja)	2006-05-09	2007-11-15	Daiichi Sankyo Company, Limited	二環性アリール誘導体
TW200811140A (en)	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en)	2006-07-06	2008-03-01	Arena Pharm Inc	Modulators of metabolism and the treatment of disorders related thereto
JP2009543805A (ja)	2006-07-13	2009-12-10	スミスクラインビーチャムコーポレーション	インドリン誘導体及びｇｐｒ１１９作動物質
TW200823182A (en)	2006-08-01	2008-06-01	Praecis Pharm Inc	Chemical compounds
WO2008016674A1 (en)	2006-08-01	2008-02-07	Praecis Pharmaceuticals Incorporated	Agonists of the sphingosine- 1- phosphate receptor (slp)
EP2099768A2 (en)	2006-08-04	2009-09-16	Praecis Pharmaceuticals Incorporated	Agonists of the sphingosine-1-phosphate receptor
RU2430925C2 (ru)	2006-08-08	2011-10-10	Киорин Фармасьютикал Ко., Лтд.	Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента
WO2008024196A1 (en)	2006-08-24	2008-02-28	Praecis Pharmaceuticals Incorporated	Chemical compounds
JP2009269819A (ja)	2006-08-25	2009-11-19	Asahi Kasei Pharma Kk	アミン化合物
JP2010501629A (ja)	2006-08-30	2010-01-21	ビオヴィトルム・アクチボラゲット（プブリクト）	Ｇｐｒ１１９関連障害を治療するためのピリジン化合物
AU2007292347A1 (en)	2006-09-07	2008-03-13	Allergan, Inc.	Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist and/or antagonist biological activity
TWI408139B (zh)	2006-09-07	2013-09-11	Actelion Pharmaceuticals Ltd	新穎噻吩衍生物
JP5253401B2 (ja)	2006-09-07	2013-07-31	アクテリオンファーマシューティカルズリミテッド	免疫調節薬としてのピリジン−４−イル誘導体
WO2008028937A1 (en)	2006-09-08	2008-03-13	Novartis Ag	N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
US8044076B2 (en)	2006-09-21	2011-10-25	Actelion Pharmaceuticals Ltd.	Phenyl derivatives and their use as immunomodulators
EP2325182A1 (en)	2006-12-06	2011-05-25	Glaxosmithkline LLC	Bicyclic compounds and use as antidiabetics
JP2010513272A (ja)	2006-12-14	2010-04-30	メルクエンドカムパニーインコーポレーテッド	アシルビピペリジニル化合物、そのような化合物を含む組成物、及び治療方法
NZ577111A (en)	2006-12-15	2012-05-25	Abbott Lab	Novel oxadiazole compounds
JO2701B1 (en)	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles
GB0625648D0 (en)	2006-12-21	2007-01-31	Glaxo Group Ltd	Compounds
WO2008079382A1 (en)	2006-12-21	2008-07-03	Abbott Laboratories	Sphingosine-1 -phosphate receptor agonist and antagonist compounds
EP2125723A1 (en)	2007-01-11	2009-12-02	Allergan, Inc.	6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
WO2008091967A1 (en)	2007-01-26	2008-07-31	Smithkline Beecham Corporation	Chemical compounds
WO2008097819A2 (en)	2007-02-05	2008-08-14	Smithkline Beecham Corporation	Chemical compounds
EP2125797B1 (en)	2007-03-16	2014-01-15	Actelion Pharmaceuticals Ltd.	Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
MX2009010060A (es)	2007-03-21	2010-01-20	Epix Pharm Inc	Compuestos moduladores del receptor de esfingosin-1-fosfato y uso de los mismos.
WO2008128832A1 (en)	2007-04-18	2008-10-30	Nicox S.A.	Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome
EA016443B1 (ru)	2007-04-19	2012-05-30	Глэксо Груп Лимитед	Оксадиазолзамещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (s1p)
ES2388967T3 (es)	2007-05-04	2012-10-22	Bristol-Myers Squibb Company	Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
EP2014653A1 (en)	2007-06-15	2009-01-14	Bioprojet	Novel dicarboxylic acid derivatives as S1P1 receptor agonists
WO2009011850A2 (en)	2007-07-16	2009-01-22	Abbott Laboratories	Novel therapeutic compounds
WO2009019506A1 (en)	2007-08-03	2009-02-12	Astrazeneca Ab	Heterocyclyc sulfonamides having edg-1 antagonistic activity
US8399448B2 (en)	2007-08-08	2013-03-19	Merck Serono Sa	6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
RU2443699C2 (ru)	2007-09-20	2012-02-27	Айрм Ллк	Соединения и композиции в качестве модуляторов активности gpr119
TW200930368A (en)	2007-11-15	2009-07-16	Astrazeneca Ab	Bis-(sulfonylamino) derivatives in therapy
EP2225201A2 (en)	2007-11-28	2010-09-08	Synta Pharmaceuticals Corp.	Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
CN101945862A (zh)	2007-12-18	2011-01-12	艾尼纳制药公司	用于治疗自身免疫性病症和炎性病症的四氢环戊二烯并[b]吲哚-3-基羧酸衍生物
JP2011510073A (ja)	2008-01-25	2011-03-31	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１アゴニストとして作用するジヒドロ−１Ｈ−ピロロ［１，２−ａ］インドール−１−イルカルボン酸誘導体
AR070398A1 (es)	2008-02-22	2010-03-31	Gruenenthal Chemie	Derivados sustituidos de indol
WO2009108924A2 (en)	2008-02-28	2009-09-03	Solar Roofing Systems, Inc.	Photovoltaic roofing tile with fire suppression
AU2009227629B2 (en)	2008-03-17	2014-09-04	Actelion Pharmaceuticals Ltd	Dosing regimen for a selective S1P1 receptor agonist
US20110263557A1 (en)	2008-04-07	2011-10-27	Irm Llc	Compounds and compositions as modulators of gpr119 activity
WO2009125434A2 (en)	2008-04-07	2009-10-15	Cadila Healthcare Limited	Oxime derivatives
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2913326B1 (en)	2008-05-14	2020-07-15	The Scripps Research Institute	Novel modulators of sphingosine phosphate receptors
WO2009151621A1 (en)	2008-06-13	2009-12-17	Arena Pharmaceuticals, Inc.	Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en)	2008-06-13	2009-12-17	Arena Pharmaceuticals, Inc.	Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
NZ590474A (en) *	2008-07-23	2012-10-26	Arena Pharm Inc	SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
CN102197038B (zh)	2008-08-27	2016-04-20	艾尼纳制药公司	用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
ES2760607T3 (es)	2008-12-22	2020-05-14	Novartis Ag	Régimen de dosificación para un agonista del receptor s1p
SI2379069T1 (sl)	2008-12-22	2015-07-31	Novartis Ag	Režim odmerjanja agonista receptorja S1P
WO2010075273A1 (en)	2008-12-23	2010-07-01	Schering Corporation	Bicyclic heterocycle derivatives and methods of use thereof
EP2382203B1 (en)	2008-12-23	2015-01-14	Merck Sharp & Dohme Corp.	Bicyclic heterocycle derivatives and methods of use thereof
WO2010074271A1 (ja)	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
JPWO2010084944A1 (ja)	2009-01-22	2012-07-19	田辺三菱製薬株式会社	新規ピロロ［２，３−ｄ］ピリミジン化合物
EP2395835A4 (en)	2009-02-10	2013-04-17	Abbott Lab	S1P5 RECEPTOR AGONISTS AND ANTAGONISTS, AND METHODS OF USE
WO2011005290A1 (en)	2009-06-23	2011-01-13	Arena Pharmaceuticals, Inc.	Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
WO2011005295A1 (en)	2009-06-24	2011-01-13	Arena Pharmaceuticals, Inc.	Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
AR077638A1 (es)	2009-07-15	2011-09-14	Lilly Co Eli	Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
WO2011030139A1 (en)	2009-09-11	2011-03-17	Astrazeneca Ab	4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
CN102686571B (zh)	2009-10-29	2015-11-25	百时美施贵宝公司	三环杂环化合物
US8299059B2 (en)	2009-10-30	2012-10-30	Eli Lilly And Company	Crystalline compound and a process for its preparation
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
MTP4285B (en)	2009-12-30	2011-07-04	Medichem Sa	A 1-(1h-1,2,3-triazol-1-yl)butan-2-ol derivative for pharmaceutical use, and the use of a 1-(1h-1, 2, 4- triazol-1yl) butan-2-ol derivative with substially undefined crystal shap for preparing said 1-(1h-1, 2, 4-triazol-1-yl0 butan-2-ol derivative
JP5856980B2 (ja)	2010-01-27	2016-02-10	アリーナファーマシューティカルズ，インコーポレイテッド	（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
EP2542554B1 (en)	2010-03-03	2015-11-04	Arena Pharmaceuticals, Inc.	Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
JP2013523819A (ja)	2010-04-06	2013-06-17	アリーナファーマシューティカルズ，インコーポレイテッド	Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
US8747844B2 (en)	2010-07-30	2014-06-10	Saint Louis University	Methods of treating pain
KR101871011B1 (ko)	2010-09-22	2018-06-25	아레나 파마슈티칼스, 인크.	Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
CN106278999B (zh)	2011-02-07	2019-10-25	比奥根Ma公司	S1p调节剂
WO2012135570A1 (en)	2011-04-01	2012-10-04	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en)	2011-04-19	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN104093310A (zh)	2012-02-03	2014-10-08	泰华制药工业有限公司	拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
US20160038506A1 (en)	2012-02-14	2016-02-11	Repros Therapeutics Inc.	Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US8962888B2 (en)	2012-12-03	2015-02-24	Physical Sciences, Inc.	Forming spherical crystal habit
JP5589110B1 (ja)	2013-03-08	2014-09-10	株式会社ポーラファルマ	晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
UA126268C2 (uk)	2015-01-06	2022-09-14	Арена Фармасьютікалз, Інк.	СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
EA201890096A1 (ru)	2015-06-22	2018-08-31	Арена Фармасьютикалз, Инк.	КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ
US11534424B2 (en)	2017-02-16	2022-12-27	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
KR20190113955A (ko)	2017-02-16	2019-10-08	아레나 파마슈티칼스, 인크.	장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
EP3801459A1 (en)	2018-06-06	2021-04-14	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
EP3860590B1 (en)	2018-10-03	2023-06-07	Arena Pharmaceuticals, Inc.	Etrasimod for use in methods for the treatment of scleroderma
AU2019387212A1 (en)	2018-11-30	2021-06-24	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
JP2022516662A (ja)	2019-01-08	2022-03-01	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態を治療する方法

2016
- 2016-06-21 EA EA201890096A patent/EA201890096A1/ru unknown
- 2016-06-21 ES ES16734529T patent/ES2929526T3/es active Active
- 2016-06-21 KR KR1020237039088A patent/KR20230160955A/ko active Application Filing
- 2016-06-21 MX MX2017016530A patent/MX2017016530A/es unknown
- 2016-06-21 CN CN201680048241.0A patent/CN108349891B/zh active Active
- 2016-06-21 US US15/738,175 patent/US10301262B2/en active Active
- 2016-06-21 SI SI201631637T patent/SI3310760T1/sl unknown
- 2016-06-21 BR BR112017027656-9A patent/BR112017027656B1/pt active IP Right Grant
- 2016-06-21 MA MA042807A patent/MA42807A/fr unknown
- 2016-06-21 IL IL285890A patent/IL285890B/en unknown
- 2016-06-21 DK DK16734529.7T patent/DK3310760T3/da active
- 2016-06-21 CA CA3002551A patent/CA3002551A1/en active Pending
- 2016-06-21 HU HUE16734529A patent/HUE060476T2/hu unknown
- 2016-06-21 KR KR1020187001785A patent/KR102603199B1/ko active IP Right Grant
- 2016-06-21 WO PCT/US2016/038506 patent/WO2016209809A1/en active Application Filing
- 2016-06-21 PT PT167345297T patent/PT3310760T/pt unknown
- 2016-06-21 PL PL16734529.7T patent/PL3310760T3/pl unknown
- 2016-06-21 EP EP21178613.2A patent/EP3939965A1/en active Pending
- 2016-06-21 EP EP16734529.7A patent/EP3310760B8/en active Active
- 2016-06-21 JP JP2017566114A patent/JP6838744B2/ja active Active
- 2016-06-21 AU AU2016284162A patent/AU2016284162A1/en not_active Abandoned
2017
- 2017-12-04 IL IL256084A patent/IL256084B/en unknown
- 2017-12-15 MX MX2021007666A patent/MX2021007666A/es unknown
2018
- 2018-10-10 HK HK18112862.0A patent/HK1253714A1/zh unknown
2019
- 2019-04-09 US US16/379,265 patent/US10676435B2/en active Active
2020
- 2020-04-30 US US16/862,681 patent/US11091435B2/en active Active
- 2020-06-22 AU AU2020204164A patent/AU2020204164B2/en active Active
- 2020-08-28 JP JP2020144358A patent/JP2020196756A/ja active Pending
2021
- 2021-07-14 US US17/375,063 patent/US11884626B2/en active Active
- 2021-10-11 AU AU2021249972A patent/AU2021249972B2/en active Active
2022
- 2022-11-24 JP JP2022187106A patent/JP2023022155A/ja active Pending
2023
- 2023-12-18 US US18/542,913 patent/US20240140911A1/en active Pending

Also Published As

Publication number	Publication date
EP3310760A1 (en)	2018-04-25
MA42807A (fr)	2018-07-25
US20190330153A1 (en)	2019-10-31
US20180186738A1 (en)	2018-07-05
MX2017016530A (es)	2018-03-12
JP2018525336A (ja)	2018-09-06
EP3939965A1 (en)	2022-01-19
EA201890096A1 (ru)	2018-08-31
JP6838744B2 (ja)	2021-03-03
HUE060476T2 (hu)	2023-03-28
WO2016209809A1 (en)	2016-12-29
NZ738862A (en)	2023-12-22
EP3310760B8 (en)	2022-10-19
BR112017027656A2 (pt)	2018-08-28
AU2016284162A1 (en)	2018-02-01
US20220002244A1 (en)	2022-01-06
CN108349891B (zh)	2022-04-05
AU2021249972B2 (en)	2022-12-15
US10301262B2 (en)	2019-05-28
US11884626B2 (en)	2024-01-30
CA3002551A1 (en)	2016-12-29
JP2023022155A (ja)	2023-02-14
JP2020196756A (ja)	2020-12-10
IL256084B (en)	2021-10-31
KR102603199B1 (ko)	2023-11-16
ES2929526T3 (es)	2022-11-29
BR112017027656B1 (pt)	2023-12-05
IL285890B (en)	2022-07-01
IL285890A (en)	2021-09-30
HK1253714A1 (zh)	2019-06-28
AU2020204164A1 (en)	2020-07-09
US10676435B2 (en)	2020-06-09
AU2020204164B2 (en)	2021-11-04
KR20180015259A (ko)	2018-02-12
IL256084A (en)	2018-02-28
SI3310760T1 (sl)	2023-02-28
US20200361869A1 (en)	2020-11-19
AU2023200978A1 (en)	2023-03-23
CN108349891A (zh)	2018-07-31
DK3310760T3 (da)	2022-10-24
EP3310760B1 (en)	2022-09-14
AU2021249972A1 (en)	2021-11-04
US11091435B2 (en)	2021-08-17
KR20230160955A (ko)	2023-11-24
US20240140911A1 (en)	2024-05-02
MX2021007666A (es)	2021-08-05
PL3310760T3 (pl)	2023-03-06

Publication	Publication Date	Title
HK1253714A1 (zh)	2019-06-28	用於s1p1受體相關病症的(r)-2-(7-(4-環戊基-3-(三氟甲基)苄基氧基)-1，2，3，4-四氫環戊並[b]吲哚-3-基)乙酸(化合物1)的結晶l-精氨酸鹽
IL281708A (en)	2021-05-31	(4)-7)-2-(R-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for use in the treatment of ulcerative colitis
SG10201500639TA (en)	2015-03-30	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
IL240030A0 (en)	2015-09-24	2-aza-bicyclo[1.2.2]heptane-3-carboxylic acid (benzyl-cyano-methyl)-modified amides inhibitors of cathepsin c
IL247901A0 (en)	2016-11-30	Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile
WO2014028589A3 (en)	2014-05-08	4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
GB2503852B (en)	2018-12-12	Compounds for the treatment of neuropsychiatric disorders
HK1206615A1 (en)	2016-01-15	Mglu2/3 antagonists for the treatment of autistic disorders mglu2/3
PH12017500089B1 (en)	2017-05-22	Aldosterone synthase inhibitors
FR2985512B1 (fr)	2014-06-20	Procede de preparation du sel de l-arginine du perindopril
PH12017500595A1 (en)	2017-08-30	Aldosterone synthase inhibitors
CA2922375C (en)	2021-06-15	Alpha-tea salt forms: compositions and uses for treating disease
IL252200A0 (en)	2017-07-31	A process for the purification of axl receptor tyrosine kinase inhibitor
UA117780C2 (uk)	2018-09-25	Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
IN2013CH01199A (pt)	2015-08-14
EP2944310A8 (en)	2016-03-09	MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
IL235215A0 (en)	2014-12-31	The l-malate salt of 7,2-diaza-spiro [4.5]7-dec yla, its derivatives and crystalline forms as ghrelin receptor agonists
TN2013000122A1 (en)	2014-06-25	Oxadiazole inhibitors of leukotriene production